Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-02 — Diagnosis, Evaluation, and Secondary Causes Tier: Tier 2
1. A 46-year-old woman with sustained hypertension has ABPM showing a nighttime dip of only 1.3% with nighttime BP consistently exceeding daytime BP. Her physician starts amlodipine. Which of the following most accurately identifies the additional pharmacological and diagnostic consideration most specifically indicated by her ABPM pattern?
A) No additional consideration is needed — confirming sustained hypertension by ABPM is the only clinical purpose of the test; the dipping pattern does not change pharmacological management
B) Her reverse-dipper pattern carries substantially elevated cardiovascular risk beyond her daytime values; the most specifically indicated additional steps are evaluation for OSA (obstructive sleep apnea) as a reversible contributor to nocturnal hypertension, and consideration of chronotherapy — shifting one antihypertensive agent to bedtime to specifically target the elevated nocturnal BP
C) Her pattern confirms masked hypertension requiring substitution of amlodipine with a RAAS inhibitor as the preferred agent for this phenotype
D) The near-absent nighttime dip reflects measurement artifact from nocturnal movement; repeat ABPM with an activity log is required before any management modification
E) Reverse dipping in women over 40 is a hormonal variant related to declining estrogen carrying no independent cardiovascular risk beyond standard daytime hypertension
ANSWER: B
Rationale:
Option B is correct: a reverse-dipper ABPM pattern carries substantially elevated cardiovascular risk — particularly for stroke and LVH (left ventricular hypertrophy) — independently of daytime values; the most specifically indicated steps are evaluation for OSA (the most common reversible cause of reverse dipping) and consideration of chronotherapy shifting one agent to bedtime to reduce nocturnal BP.
Option A: Option A is incorrect — the dipping pattern has specific management and diagnostic implications beyond confirming the diagnosis.
Option C: Option C is incorrect — reverse dipping is not masked hypertension, and the phenotype does not dictate a specific drug class.
Option D: Option D is incorrect — validated ABPM devices are not systematically affected by movement artifact; the reverse-dipping pattern reflects a genuine physiological abnormality.
Option E: Option E is incorrect — reverse dipping is an independent cardiovascular risk factor in both sexes and is not a hormonal variant.
2. A 59-year-old man with hypertension, CKD stage 3b (eGFR 38 mL/min/1.73m²), and potassium 5.2 mEq/L is on lisinopril 40 mg daily with BP of 158/96 mmHg. His nephrologist wants to add spironolactone as a fourth agent for resistant hypertension. Which of the following most accurately identifies the primary risk and the appropriate alternative?
A) Spironolactone can be added safely when potassium is below 5.5 mEq/L regardless of eGFR; the combination with lisinopril provides additive renal protection and the potassium of 5.2 mEq/L does not represent a contraindication
B) The ACE inhibitor should be discontinued before spironolactone is added because the combination of two RAAS-active agents is the primary risk; once lisinopril is stopped spironolactone can be safely initiated
C) Spironolactone is absolutely contraindicated at any eGFR below 45 mL/min/1.73m² and the recommendation should be refused based on this absolute threshold
D) The primary risk is the combination of an ACE inhibitor plus spironolactone in a patient with eGFR 38 and baseline potassium already 5.2 mEq/L — both agents suppress aldosterone-mediated potassium excretion through complementary mechanisms, and CKD-impaired renal potassium excretion creates substantial risk of life-threatening hyperkalemia; a safer alternative fourth agent is amlodipine, or a loop diuretic for volume control, with potassium binders considered if spironolactone is deemed essential
E) The primary risk of adding spironolactone is gynecomastia; eplerenone should be substituted to eliminate this off-target effect while providing equivalent cardiorenal protection
ANSWER: D
Rationale:
Option D is correct: ACE inhibitor plus spironolactone in a patient with eGFR 38 and baseline potassium 5.2 mEq/L creates high risk of life-threatening hyperkalemia — both agents suppress aldosterone-mediated potassium excretion through complementary mechanisms (ACE inhibitor reduces aldosterone production; spironolactone blocks the mineralocorticoid receptor), and CKD impairs the renal capacity to excrete the resulting potassium load.
Option A: Option A is incorrect — a potassium of 5.2 mEq/L with eGFR 38 on an ACE inhibitor is not a safe baseline for adding spironolactone; the 5.5 mEq/L threshold ignores the CKD-driven inability to excrete a further potassium load.
Option B: Option B is incorrect — stopping the ACE inhibitor and adding spironolactone trades one risk for another and does not address the fundamental concern; it is not the standard approach.
Option C: Option C is incorrect — there is no absolute eGFR threshold of 45 mL/min/1.73m²; the decision requires individualized risk-benefit analysis.
Option E: Option E is incorrect — while gynecomastia is a real spironolactone side effect, it is not the primary safety concern in this patient; life-threatening hyperkalemia is the immediate risk.
3. A 52-year-old woman with newly diagnosed hypertension and systemic lupus erythematosus (SLE) on hydroxychloroquine presents with BP 162/98 mmHg and urine ACR (albumin-to-creatinine ratio) 260 mg/g. Renal biopsy confirms lupus nephritis Class III. Which antihypertensive approach is most appropriate, and which agent is specifically contraindicated in this patient because of her SLE?
A) Thiazide diuretics are first-line in lupus nephritis because aldosterone-mediated sodium retention is the dominant mechanism of hypertension in immune complex glomerular disease
B) Beta-blockers are preferred in lupus nephritis because reducing SNS (sympathetic nervous system) tone lowers the cytokine-driven inflammatory cascade that underlies the renal injury
C) Hydralazine is the preferred vasodilator in lupus nephritis because it reduces systemic vascular resistance without affecting renal blood flow; ACE inhibitors are contraindicated in lupus nephritis because efferent vasodilation worsens hematuria
D) Hydralazine should be specifically avoided in this patient with established SLE because hydralazine is a well-recognized cause of drug-induced lupus erythematosus (DILE) — layering DILE on top of existing SLE complicates disease monitoring, serology interpretation, and management; an ACE inhibitor or ARB is the preferred antihypertensive given the proteinuric glomerular disease
E) Calcium channel blockers are absolutely contraindicated in lupus nephritis because dihydropyridine-induced afferent vasodilation worsens immune complex deposition in the glomerulus
ANSWER: D
Rationale:
Option D is correct: hydralazine is a well-recognized cause of drug-induced lupus erythematosus (DILE) through interference with DNA methylation in T-lymphocytes; in a patient with established SLE, adding hydralazine risks superimposing DILE on active SLE, complicating disease monitoring and serological interpretation; ACE inhibitors or ARBs are the preferred antihypertensives given the proteinuric nephritis, providing intraglomerular pressure reduction and albuminuria reduction beyond BP lowering.
Option A: Option A is incorrect — thiazides do not specifically address the intraglomerular pressure mechanism relevant to immune complex nephritis.
Option B: Option B is incorrect — beta-blockers do not reduce the cytokine-driven inflammatory injury in lupus nephritis.
Option C: Option C is incorrect — ACE inhibitors are not contraindicated in lupus nephritis; they are actually specifically indicated by the proteinuria; and hydralazine's contraindication here is because of DILE risk, not a preference for it.
Option E: Option E is incorrect — dihydropyridine CCBs are not contraindicated in lupus nephritis; this mechanism is fabricated.
4. A 68-year-old man with hypertension, type 2 diabetes, and CKD stage 3a is on lisinopril 10 mg daily (BP 134/82 mmHg, potassium 4.4 mEq/L, eGFR 54). His endocrinologist adds empagliflozin (an SGLT-2 — sodium-glucose cotransporter-2 — inhibitor) for glycemic control. Eight weeks later his BP is 128/76 mmHg and urine ACR has fallen from 88 to 41 mg/g. Which of the following best explains the BP and ACR reduction beyond glycemic effect?
A) Empagliflozin reduces BP through direct inhibition of the renin-angiotensin-aldosterone system (RAAS) at the proximal tubule, producing additive Ang II suppression on top of lisinopril
B) The BP and ACR reduction reflect weight loss from glucosuria — caloric loss through urinary glucose excretion reduces adipose tissue mass, lowering leptin-driven SNS activation; this is the primary mechanism
C) Empagliflozin blocks L-type calcium channels in vascular smooth muscle as an off-target pharmacological effect, producing vasodilation that additively lowers BP alongside lisinopril
D) The ACR reduction reflects SGLT-2 inhibitor-mediated reduction in glomerular basement membrane glycosylation through improved glycemic control; the BP reduction is an unrelated effect of reduced dietary sodium intake following diabetes education at the same visit
E) SGLT-2 inhibition blocks proximal tubular glucose and sodium co-transport, producing osmotic diuresis and natriuresis that reduce intravascular volume and BP; simultaneously, increased sodium delivery to the macula densa activates tubuloglomerular feedback, constricting the afferent arteriole and reducing intraglomerular hydraulic pressure — a mechanism complementary to and additive with lisinopril's efferent vasodilation, explaining both the BP reduction and the ACR fall
ANSWER: E
Rationale:
Option E is correct: SGLT-2 inhibitors produce osmotic diuresis and natriuresis by blocking proximal tubular glucose-sodium co-transport, reducing intravascular volume and lowering BP; simultaneously, the increased distal sodium delivery activates tubuloglomerular feedback, constricting the afferent arteriole and reducing intraglomerular pressure — complementary to lisinopril's efferent vasodilation — explaining both the BP reduction and ACR fall through additive glomerular protection.
Option A: Option A is incorrect — SGLT-2 inhibitors do not directly inhibit the RAAS; any renin modulation is indirect through volume changes.
Option B: Option B is incorrect — while weight loss does contribute, the BP and ACR benefits occur rapidly and independently of weight change, confirming a hemodynamic mechanism.
Option C: Option C is incorrect — SGLT-2 inhibitors do not block L-type calcium channels; this mechanism is fabricated.
Option D: Option D is incorrect — the ACR reduction occurs rapidly before meaningful glycemic improvement can restore glomerular basement membrane integrity, confirming a hemodynamic rather than a glycemic mechanism.
5. A 33-year-old woman with hypertension has plasma cortisol of 2.2 mcg/dL after a 1 mg overnight dexamethasone suppression test (DST). She has no cushingoid features and a normal BMI. Which of the following most accurately interprets this result and identifies the next step?
A) A cortisol of 2.2 mcg/dL after overnight DST is a positive screening result (above the suppression threshold of <1.8 mcg/dL) requiring confirmation with a second biochemical test — 24-hour urinary free cortisol or late-night salivary cortisol — before a diagnosis of Cushing syndrome can be established; false positives are common with obesity, depression, alcoholism, and medications that accelerate dexamethasone metabolism (phenytoin, rifampicin, carbamazepine); physical absence of cushingoid features does not exclude the diagnosis at this screening stage
B) A cortisol of 2.2 mcg/dL is diagnostic of Cushing syndrome; pituitary MRI should be ordered immediately to identify the source
C) A cortisol of 2.2 mcg/dL is within the normal suppression range (threshold is <2.5 mcg/dL in most reference laboratories) and the test is negative; no further evaluation for Cushing syndrome is warranted
D) The overnight DST is not a validated screening test for hypertension-related Cushing syndrome; the correct initial screening test is plasma ACTH — adrenocorticotropic hormone — measurement, which should be ordered instead
E) A cortisol of 2.2 mcg/dL confirms adrenal insufficiency — the adrenal gland has failed to produce adequate cortisol in response to dexamethasone stimulation, confirming primary adrenal dysfunction as the cause of her hypertension
ANSWER: A
Rationale:
Option A is correct: cortisol 2.2 mcg/dL after overnight DST exceeds the suppression threshold of <1.8 mcg/dL, making it a positive screening result that requires confirmation — false positives are common and this screening test alone is not diagnostic; 24-hour urinary free cortisol or late-night salivary cortisol is the appropriate confirmatory next step.
Option B: Option B is incorrect — the DST alone is not diagnostic and does not establish etiology; pituitary MRI is a localization step that comes after biochemical confirmation.
Option C: Option C is incorrect — the standard DST threshold is <1.8 mcg/dL, not <2.5 mcg/dL; 2.2 mcg/dL is a positive screening result by established criteria.
Option D: Option D is incorrect — the 1 mg overnight DST is the validated Endocrine Society first-line screening tool for Cushing syndrome; plasma ACTH is a differentiation step used after the diagnosis is confirmed.
Option E: Option E is incorrect — adrenal insufficiency produces consistently low cortisol; it does not cause failure to suppress after dexamethasone, and it is not associated with hypertension.
6. A 41-year-old man with hypertension and migraines presents for antihypertensive selection. BP is 154/96 mmHg on no medications. His neurologist has recommended migraine prophylaxis. Which of the following antihypertensive agents provides established dual efficacy for both hypertension and migraine prophylaxis, and what is the shared pharmacological basis?
A) Amlodipine — dihydropyridine CCBs prevent migraine by blocking L-type calcium channels in trigeminal ganglion neurons, reducing calcitonin gene-related peptide (CGRP) release and cortical spreading depression
B) Lisinopril — ACE inhibitor-mediated bradykinin accumulation activates inhibitory CNS pathways that prevent cortical spreading depression, making ACE inhibitors the most evidence-based agents for migraine prophylaxis among antihypertensives
C) Propranolol or metoprolol — beta-blockers are Level A evidence, first-line pharmacological migraine prophylaxis, with mechanisms including reduction of sympathetically mediated cerebrovascular reactivity and modulation of serotonergic brainstem pathways; they simultaneously lower BP through beta-1 blockade reducing cardiac output
D) Hydrochlorothiazide — thiazide-mediated extracellular volume reduction lowers intracranial pressure, which reduces the cortical pressure waves that trigger spreading depression in migraine
E) Candesartan — all ARBs have demonstrated Level A evidence for migraine prophylaxis equivalent to beta-blockers in head-to-head randomized trials, and candesartan is the first-line agent when beta-blockers are not tolerated
ANSWER: C
Rationale:
Option C is correct: beta-blockers — specifically propranolol (non-selective) and metoprolol (beta-1 selective) — are Level A evidence, first-line pharmacological migraine prophylaxis in major headache society guidelines; their mechanism in migraine involves reduction of sympathetically mediated cerebrovascular reactivity and modulation of serotonergic pathways, and they simultaneously lower BP through beta-1 blockade; a single agent serves both indications.
Option A: Option A is incorrect — dihydropyridine CCBs including amlodipine do not have Level A evidence for migraine prophylaxis; verapamil has modest evidence for cluster headache, not migraine.
Option B: Option B is incorrect — while lisinopril has been studied in one small migraine prophylaxis trial, it is not guideline-recommended as a first-line agent and does not have the evidence base of beta-blockers.
Option D: Option D is incorrect — thiazide diuretics have no established role in migraine prophylaxis through the mechanism described.
Option E: Option E is incorrect — candesartan has modest evidence from small trials but is not classified as Level A evidence equivalent to beta-blockers; not all ARBs have demonstrated equivalent prophylaxis efficacy.
7. A 55-year-old man with hypertension and atrial fibrillation on warfarin has BP of 158/96 mmHg on amlodipine 5 mg. His cardiologist wants to add a rate-controlling agent for AF that also intensifies BP control. Which of the following correctly identifies the preferred agent and the most clinically significant drug interaction to monitor?
A) Metoprolol succinate — beta-1 blockade controls ventricular rate and lowers BP; the most important interaction is that beta-blockers inhibit CYP2C9, substantially increasing warfarin levels and requiring INR (international normalized ratio) monitoring
B) Amiodarone — controls ventricular rate through multiple ion channel effects and lowers BP through alpha-adrenergic blockade; the most clinically significant interaction is potent CYP2C9 inhibition by amiodarone and its metabolite desethylamiodarone, which markedly increases S-warfarin levels by 30–50% or more; this effect persists for weeks to months after amiodarone discontinuation due to its extremely long half-life (40–55 days), mandating significant warfarin dose reduction and frequent INR monitoring
C) Diltiazem — non-dihydropyridine CCB slowing AV nodal conduction and lowering BP; the most important interaction is CYP3A4 inhibition raising warfarin levels requiring INR monitoring
D) Digoxin — controls ventricular rate through vagal enhancement and lowers BP through improved cardiac output; the most important interaction is digoxin-warfarin competition for renal tubular secretion raising digoxin toxicity risk
E) Flecainide — sodium channel blockade controls ventricular rate and lowers BP through negative inotropy; the most important interaction is plasma protein binding competition with warfarin increasing bleeding risk
ANSWER: B
Rationale:
Option B is correct: amiodarone achieves both rate control in AF (through AV nodal blockade) and BP reduction (through alpha-1 adrenergic blockade), and its interaction with warfarin is among the most clinically significant in cardiovascular pharmacology — potent CYP2C9 inhibition increases S-warfarin levels by 30–50% or more, with the effect persisting weeks to months after discontinuation due to amiodarone's extremely long half-life, requiring substantial warfarin dose reduction and frequent INR monitoring.
Option A: Option A is incorrect — beta-blockers do not significantly inhibit CYP2C9 and do not meaningfully alter warfarin levels through this mechanism.
Option C: Option C is incorrect — diltiazem and verapamil do modestly inhibit CYP3A4 and P-glycoprotein with some effect on warfarin levels, but the magnitude and clinical severity is far less than the amiodarone-warfarin interaction.
Option D: Option D is incorrect — digoxin controls ventricular rate but does not lower BP through improved cardiac output in the manner described, and the digoxin-warfarin interaction mechanism is fabricated.
Option E: Option E is incorrect — flecainide is a rhythm control agent, not a rate control agent, and the interaction mechanism described is fabricated.
8. A 48-year-old woman with hypertension and Raynaud's phenomenon (episodic digital vasospasm triggered by cold) presents for antihypertensive selection. BP is 160/98 mmHg. Which antihypertensive is most likely to worsen her Raynaud's symptoms, and which is specifically beneficial for both conditions?
A) ACE inhibitors most likely worsen Raynaud's through bradykinin-mediated paradoxical vasoconstriction in digital arterioles; dihydropyridine CCBs are specifically beneficial for both conditions
B) Thiazide diuretics most likely worsen Raynaud's through volume depletion activating sympathetic vasoconstriction in digital vessels; a CCB is the preferred alternative
C) Dihydropyridine CCBs most likely worsen Raynaud's through preferential dilation of afferent arterioles in the kidney, redistributing blood flow away from peripheral digital vessels and worsening digital ischemia during cold exposure
D) Non-selective beta-blockers most likely worsen Raynaud's by blocking beta-2-mediated vasodilation in peripheral arterioles, leaving alpha-1-mediated vasoconstriction unopposed in the digits during cold or sympathetic activation; dihydropyridine CCBs such as amlodipine or nifedipine are specifically beneficial for both conditions because they directly vasodilate peripheral arterioles through L-type calcium channel blockade, and are established first-line pharmacological therapy for Raynaud's phenomenon
E) ARBs most likely worsen Raynaud's through AT2 (angiotensin type 2) receptor blockade at high doses, eliminating AT2-mediated digital vasodilation during cold exposure
ANSWER: D
Rationale:
Option D is correct: non-selective beta-blockers (propranolol, nadolol) worsen Raynaud's by blocking beta-2-mediated peripheral vasodilation while leaving alpha-1-mediated vasoconstriction from sympathetic activation unopposed in the digits; dihydropyridine CCBs are the specifically beneficial dual-indication agent, directly vasodilating peripheral arterioles and representing established first-line pharmacological therapy for Raynaud's phenomenon.
Option A: Option A is incorrect — ACE inhibitors do not cause paradoxical digital vasoconstriction through bradykinin and are not specifically identified as problematic in Raynaud's management.
Option B: Option B is incorrect — while volume depletion could theoretically worsen sympathetic tone, thiazides are not specifically contraindicated in Raynaud's and are not the primary concern.
Option C: Option C is incorrect — dihydropyridine CCBs are the preferred treatment for Raynaud's, not the agent to avoid; the mechanism described (redistribution of blood flow from digits) is fabricated.
Option E: Option E is incorrect — ARBs block AT1 (angiotensin type 1), not AT2 receptors; this mechanism for worsening Raynaud's is fabricated.
9. A 57-year-old man with hypertension is found on routine labs to have potassium 6.1 mEq/L. He is on lisinopril 20 mg, spironolactone 25 mg, and trimethoprim-sulfamethoxazole (TMP-SMX) started 6 days ago for a urinary tract infection. His baseline potassium before the antibiotic was 4.9 mEq/L and renal function is stable (eGFR 62). Which of the following most accurately explains the hyperkalemia?
A) The hyperkalemia reflects disease progression causing acute tubular injury; both the ACE inhibitor and spironolactone should be permanently discontinued and nephrology should be urgently consulted
B) TMP-SMX causes hyperkalemia by blocking the epithelial sodium channel (ENaC) in the collecting duct principal cells — the identical mechanism as amiloride — reducing sodium reabsorption and the electrochemical gradient for potassium secretion; in a patient already on an ACE inhibitor (which reduces aldosterone-mediated ENaC upregulation) and spironolactone (which blocks the mineralocorticoid receptor driving ENaC expression), trimethoprim creates a triple combination that blocks potassium excretion at three complementary levels; TMP-SMX should be discontinued and an alternative antibiotic prescribed
C) The hyperkalemia is caused by TMP-SMX-induced acute kidney injury, which has reduced GFR below the threshold for adequate potassium excretion; the lisinopril and spironolactone are not contributing
D) The hyperkalemia reflects a CYP2D6 interaction between TMP-SMX and lisinopril producing toxic lisinopril accumulation that overwhelms renal potassium excretion capacity
E) Doubling the spironolactone dose will correct the hyperkalemia through a paradoxical stimulation of aldosterone-independent potassium excretion pathways in the collecting duct
ANSWER: B
Rationale:
Option B is correct: trimethoprim blocks ENaC in the collecting duct principal cells — the identical mechanism as amiloride — reducing the sodium entry that drives the electrochemical gradient for potassium secretion; in this patient already on an ACE inhibitor (reducing aldosterone production) and spironolactone (blocking the mineralocorticoid receptor), trimethoprim adds a third layer of potassium excretion blockade, explaining the clinically dangerous hyperkalemia; TMP-SMX should be discontinued and an alternative antibiotic (nitrofurantoin or a fluoroquinolone based on susceptibility) substituted.
Option A: Option A is incorrect — the hyperkalemia is pharmacologically explained and does not represent irreversible tubular injury; permanent RAAS discontinuation is not indicated.
Option C: Option C is incorrect — TMP-SMX does not cause AKI through nephrotoxic mechanisms at standard doses; the mechanism is ENaC blockade, not reduced GFR.
Option D: Option D is incorrect — the mechanism is ENaC blockade by trimethoprim, not a CYP2D6 pharmacokinetic interaction; lisinopril is not significantly metabolized by CYP2D6.
Option E: Option E is incorrect — doubling spironolactone would worsen hyperkalemia by further blocking mineralocorticoid receptor-driven ENaC expression; the "paradoxical" excretion effect is fabricated.
10. A 62-year-old woman with resistant hypertension (BP 164/102 mmHg on maximum-dose lisinopril, amlodipine, and chlorthalidone with confirmed adherence) has normal renal function, a normal ARR (aldosterone-to-renin ratio), and no identified secondary causes. Which of the following represents the most evidence-based next pharmacological step, and what is the mechanistic rationale?
A) Add hydralazine as the fourth agent — direct arterial vasodilation through smooth muscle cGMP-independent mechanisms overcomes neurohormonal resistance that is unresponsive to standard drug classes
B) Add an ARB alongside the existing ACE inhibitor to achieve dual RAAS blockade — the additional suppression of aldosterone through both Ang II reduction and AT1 receptor blockade provides additive BP reduction in resistant hypertension
C) Refer immediately for catheter-based renal denervation — pharmacological therapy has failed by definition after three-drug failure and guideline-mandated renal denervation is the next step
D) Add spironolactone 25–50 mg daily — the PATHWAY-2 trial (a randomized crossover trial demonstrating spironolactone superiority as fourth-line agent in resistant hypertension) showed that aldosterone-mediated volume expansion is the dominant mechanism in true resistant hypertension even when the formal ARR is not diagnostically elevated, making mineralocorticoid receptor antagonism the most evidence-based fourth-line agent
E) Add clonidine — central alpha-2 agonism suppresses sympathetic outflow through a mechanism entirely distinct from the existing three drug classes and is the guideline-mandated standard fourth-line agent for resistant hypertension
ANSWER: D
Rationale:
Option D is correct: PATHWAY-2 demonstrated that spironolactone at 25–50 mg daily produces substantially greater additional BP reduction than bisoprolol, doxazosin, or placebo as a fourth agent in true resistant hypertension — the mechanistic basis is that aldosterone-mediated volume expansion is the dominant driver even when the formal ARR is not diagnostically elevated; spironolactone is now the guideline-recommended fourth-line agent for resistant hypertension.
Option A: Option A is incorrect — hydralazine is not the evidence-based fourth-line agent for resistant hypertension and is associated with reflex tachycardia and lupus-like syndrome with prolonged use.
Option B: Option B is incorrect — dual RAAS blockade combining ACE inhibitors and ARBs was evaluated in the ONTARGET trial (a dual RAAS blockade trial — ramipril plus telmisartan — showing increased AKI and hyperkalemia without cardiovascular benefit over monotherapy) and is not recommended.
Option C: Option C is incorrect — renal denervation is investigational with emerging evidence but is not the guideline-mandated next step after three-drug failure; pharmacological options remain first.
Option E: Option E is incorrect — clonidine is sometimes used as a fourth agent but lacks the robust randomized controlled trial (RCT) evidence supporting spironolactone and carries significant risks including rebound hypertension on abrupt discontinuation.
11. A 70-year-old man with isolated systolic hypertension (ISH — systolic BP 178 mmHg, diastolic BP 68 mmHg), moderate cognitive impairment, and a hip fracture 6 months ago is evaluated for antihypertensive intensification. His geriatrician is concerned about the risks of aggressive BP lowering in this frail patient. Which of the following most accurately frames the evidence-based approach?
A) BP should be lowered aggressively to below 120/80 mmHg in all patients regardless of age, frailty, or cognitive status, as SPRINT (a trial of intensive vs standard BP targets — systolic blood pressure (SBP) goal 120 vs 140 mmHg — in high-risk non-diabetic adults) demonstrated uniform cardiovascular benefit across all subgroups including the elderly
B) Antihypertensive therapy should be discontinued entirely in patients over 70 with cognitive impairment and prior falls, as any BP lowering in this demographic carries net harm without cardiovascular benefit
C) A conservative approach targeting SBP 140–150 mmHg is appropriate in this frail elderly patient — aggressive BP lowering in older frail adults with cognitive impairment, orthostatic hypotension risk, and prior falls carries risks of falls, syncope, AKI, and cognitive worsening that may outweigh the cardiovascular benefit; agent selection should favor agents with low orthostatic hypotension risk and avoid excessive diastolic lowering given the already low diastolic blood pressure (DBP) of 68 mmHg
D) Beta-blockers are the preferred antihypertensive in all elderly patients with ISH because their negative chronotropic effect prevents reflex tachycardia from the low diastolic pressure, protecting against coronary hypoperfusion
E) CCBs are absolutely contraindicated in frail elderly patients with ISH because their afferent vasodilatory mechanism lowers diastolic pressure preferentially, worsening the already low DBP of 68 mmHg and precipitating coronary hypoperfusion
ANSWER: C
Rationale:
Option C is correct: in frail elderly patients with cognitive impairment, prior falls, and very low diastolic BP, aggressive BP lowering carries risks that may outweigh cardiovascular benefit; the SPRINT trial excluded patients with dementia and used automated unattended BP measurements (typically 5–10 mmHg lower than standard office readings), limiting applicability to this population; a conservative SBP target of 140–150 mmHg with agent selection favoring low orthostatic hypotension risk is appropriate.
Option A: Option A is incorrect — SPRINT excluded patients with dementia and its results are not directly applicable to frail, cognitively impaired patients.
Option B: Option B is incorrect — evidence supports treating hypertension in patients over 70 including those with frailty, but with individualized conservative targets; complete discontinuation is not appropriate.
Option D: Option D is incorrect — beta-blockers primarily reduce cardiac output and have less effect on the arterial stiffness driving ISH; they are not preferred for ISH in the elderly and can worsen exercise intolerance.
Option E: Option E is incorrect — dihydropyridine CCBs do not preferentially lower diastolic pressure in ISH; they are actually reasonable agents in this setting and are not contraindicated in frail elderly patients.
12. A 44-year-old woman develops angioedema — facial swelling without urticaria — 3 weeks after starting ramipril. The ramipril is stopped and the swelling resolves over 48 hours. Six months later her BP is again uncontrolled and her physician wants to start sacubitril-valsartan for its cardiovascular outcome benefits. Which of the following most accurately describes the risk of this decision?
A) Sacubitril-valsartan is absolutely safe after ACE inhibitor angioedema because the valsartan component is an ARB that does not affect ACE activity, and the sacubitril component blocks neprilysin rather than ACE
B) Sacubitril-valsartan carries the same angioedema risk as a plain ARB in this patient because sacubitril's effect on neprilysin does not influence bradykinin metabolism
C) Sacubitril-valsartan is specifically contraindicated after ACE inhibitor-induced angioedema — sacubitril inhibits neprilysin, one of the enzymes that normally degrades bradykinin; in a patient who has already demonstrated bradykinin-mediated vascular permeability from ACE inhibitor-induced bradykinin accumulation, adding neprilysin inhibition substantially increases the risk of recurrent angioedema by impairing a second bradykinin degradation pathway; a plain ARB (which does not affect ACE or neprilysin and does not impair bradykinin degradation) carries a lower risk and is the appropriate alternative
D) All RAAS inhibitors including ARBs are absolutely contraindicated after ACE inhibitor-induced angioedema because all classes produce identical bradykinin accumulation; the only safe antihypertensives in this patient are CCBs and thiazides
E) The angioedema was likely allergic (IgE-mediated) rather than bradykinin-mediated because it occurred only after 3 weeks; sacubitril-valsartan is therefore safe because IgE-mediated reactions are drug-specific and do not cross-react with structurally unrelated agents
ANSWER: C
Rationale:
Option C is correct: sacubitril inhibits neprilysin, which is one of the enzymes (along with ACE itself and aminopeptidase P) that normally degrades bradykinin; in a patient who has demonstrated bradykinin-mediated angioedema from ACE inhibitor use, adding neprilysin inhibition impairs a second bradykinin degradation pathway, substantially increasing the risk of recurrent angioedema; sacubitril-valsartan is specifically contraindicated after ACE inhibitor angioedema; a plain ARB — which does not affect ACE or neprilysin and does not impair bradykinin degradation — carries lower risk.
Option A: Option A is incorrect — the sacubitril component does affect bradykinin metabolism through neprilysin inhibition; the combination is not safe after ACE inhibitor angioedema.
Option B: Option B is incorrect — neprilysin inhibition does directly affect bradykinin metabolism; the risk is higher than that of a plain ARB in this patient.
Option D: Option D is incorrect — plain ARBs do not inhibit ACE or neprilysin and do not directly impair bradykinin degradation; they carry a lower but non-zero risk and are a reasonable alternative.
Option E: Option E is incorrect — ACE inhibitor angioedema is bradykinin-mediated (not IgE-mediated) and typically presents weeks after initiation; the 3-week onset is consistent with bradykinin-mediated angioedema, not inconsistent with it.
13. A 65-year-old man with hypertension and well-controlled type 2 diabetes on insulin is started on metoprolol succinate for newly diagnosed hypertension. At follow-up he reports that his hypoglycemia awareness has diminished — he no longer experiences the palpitations and tremor that previously warned him of low blood glucose. Which of the following best explains this adverse effect and identifies the safer antihypertensive alternative?
A) Metoprolol causes hypoglycemia directly by blocking beta-2 receptors on pancreatic alpha cells, suppressing glucagon release and eliminating the counterregulatory response to low blood glucose
B) Beta-blockers mask the adrenergic symptoms of hypoglycemia — palpitations, tremor, and anxiety — by blocking the sympathetic response to falling blood glucose; sweating (a cholinergic response) is preserved and should be used as an alternative warning sign; a dihydropyridine CCB such as amlodipine does not affect adrenergic hypoglycemia awareness and is a safer antihypertensive alternative in insulin-treated diabetic patients who rely on these warning symptoms
C) Beta-1 selective blockade impairs hypoglycemia awareness only through preventing tachycardia — as tachycardia is the sole adrenergic warning of hypoglycemia, beta-1 selective agents cause equivalent masking to non-selective beta-blockers; switching to a non-selective beta-blocker would therefore make no difference
D) Metoprolol causes hypoglycemia awareness impairment by inhibiting hepatic glucokinase through beta-1 receptor pathways, preventing hepatic glucose sensing and eliminating the sympathoadrenal activation that generates warning symptoms
Option B is correct: beta-blockers blunt the adrenergic warning symptoms of hypoglycemia — palpitations, tremor, and anxiety — by blocking the sympathetic response; sweating is a cholinergic response and is preserved, and patients should be counseled to rely on it; additionally, beta-2 blockade at higher doses impairs hepatic glycogenolysis, potentially prolonging hypoglycemia; amlodipine does not affect adrenergic signaling or hypoglycemia awareness.
Option A: Option A is incorrect — glucagon release from pancreatic alpha cells is impaired by beta-2 blockade, but this is a secondary mechanism; the primary clinical issue is masking of adrenergic warning symptoms, not direct hypoglycemia induction.
Option C: Option C is incorrect — hypoglycemia awareness involves the full adrenergic symptom complex including tachycardia, palpitations, tremor, and anxiety; all are blunted by beta-blockers regardless of beta-1 selectivity, though at higher doses non-selective agents have greater impairment through beta-2 blockade.
Option D: Option D is incorrect — beta-blockers do not inhibit hepatic glucokinase through beta-1 receptor pathways; this mechanism is fabricated.
Option E: Option E is incorrect — beta-blockers do not cause diabetic autonomic neuropathy; this is a disease-related complication, not a drug-induced one.
14. A 58-year-old woman with hypertension presents with a new diagnosis of primary aldosteronism confirmed by ARR and saline infusion test. Adrenal CT shows a 2.2 cm right adrenal nodule and no left adrenal abnormality. She is a surgical candidate. Her physician proceeds directly to right adrenalectomy based on the CT findings alone. Which of the following most accurately identifies the error in this approach and its consequence?
A) The physician should have performed a confirmatory saline infusion test before ordering the CT — proceeding to CT before biochemical confirmation is the primary error
B) The physician should have ordered a 24-hour urine aldosterone instead of relying on the saline infusion test — the urine test is the gold standard for confirmation and CT findings cannot be interpreted without it
C) Adrenal CT has an approximately 40% error rate in distinguishing a unilateral aldosterone-producing adenoma from bilateral adrenal hyperplasia or a non-functional incidentaloma with contralateral bilateral hyperplasia — proceeding to adrenalectomy without adrenal vein sampling (AVS) risks operating on the wrong side or on a patient with bilateral hyperplasia, in whom surgery will not cure the hypertension; AVS is required in most surgical candidates to accurately confirm unilateral excess before adrenalectomy
D) The error is that CT imaging is not required before adrenalectomy — AVS alone is sufficient to lateralize aldosterone excess and CT adds no useful information to the surgical decision
E) The physician should have started spironolactone for 6 months before ordering any imaging — MR antagonist therapy is mandatory before surgical evaluation to demonstrate that pharmacological management is insufficient
ANSWER: C
Rationale:
Option C is correct: adrenal CT has approximately 40% error rate in distinguishing a unilateral aldosterone-producing adenoma from bilateral hyperplasia or an incidentaloma in one adrenal alongside hyperplasia in the other; proceeding directly to adrenalectomy without AVS risks operating on the wrong side or on a patient with bilateral hyperplasia in whom surgery will not cure the hypertension — cure or significant improvement after adrenalectomy requires accurate lateralization confirming unilateral excess, which only AVS can reliably provide.
Option A: Option A is incorrect — the biochemical confirmation step (saline infusion test) was performed correctly; the error came in the lateralization step.
Option B: Option B is incorrect — the saline infusion test is a valid confirmatory test; the error was in proceeding to surgery based on CT alone.
Option D: Option D is incorrect — CT is a useful and necessary step in the workup (it identifies adrenal masses, rules out obvious carcinoma by size and imaging characteristics), but it is insufficient for lateralization without AVS.
Option E: Option E is incorrect — pre-surgical spironolactone treatment is given to prepare the contralateral adrenal for the hormonal shift after surgery, but it is not mandatory for 6 months before surgical evaluation and its absence is not the primary error here.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.